Capsaicin
Peripheral Nervous System Diseases
Samyang Biopharmaceuticals CorporationSmall moleculePhase 3Dormant
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 74/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Peripheral Nervous System Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxcarbamezapine Søren H. Sindrup | Phase 4 | BB |
Ngx-4010, 8% Capsaicin Patch NeurogesX | Phase 3 | BB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- United States Naval Medical Center, San Diego | Phase 4 | BB |
Adezunap Apurano Pharmaceuticals GmbH | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
View all 11 →
Same molecule, other indications
Capsaicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →